Ascletis Pharma Inc. has announced favorable results from its U.S. Phase Ib multiple ascending dose study of the ASC30 oral once-daily tablet. The study demonstrated that ASC30 achieved approximately 2.3-fold to 3.3-fold greater drug exposure compared to orforglipron. The data, obtained from a randomized, double-blind, placebo-controlled trial involving participants with obesity, showed drug exposures of 3,560 ng.h/mL and 5,060 ng.h/mL for 20 mg and 40 mg doses, respectively. These results were consistent with placebo-adjusted mean body weight reductions from baseline of 4.5% and 6.5% after a 28-day treatment period. Topline data from the upcoming U.S. Phase IIa study for ASC30 in participants with obesity or overweight are expected in the fourth quarter of 2025.